Geode Capital Management LLC Has $44.67 Million Stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Geode Capital Management LLC grew its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 1.5% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 920,363 shares of the company’s stock after buying an additional 14,015 shares during the period. Geode Capital Management LLC owned approximately 1.91% of Amphastar Pharmaceuticals worth $44,674,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in AMPH. Victory Capital Management Inc. lifted its holdings in Amphastar Pharmaceuticals by 10.9% in the 3rd quarter. Victory Capital Management Inc. now owns 218,531 shares of the company’s stock worth $10,605,000 after purchasing an additional 21,530 shares during the last quarter. International Assets Investment Management LLC acquired a new stake in shares of Amphastar Pharmaceuticals in the third quarter worth $11,070,000. Intech Investment Management LLC bought a new stake in shares of Amphastar Pharmaceuticals during the 2nd quarter worth $426,000. XTX Topco Ltd acquired a new position in Amphastar Pharmaceuticals in the 3rd quarter valued at $674,000. Finally, Wellington Management Group LLP bought a new position in Amphastar Pharmaceuticals in the 3rd quarter worth $957,000. Institutional investors own 65.09% of the company’s stock.

Analyst Upgrades and Downgrades

AMPH has been the subject of a number of recent analyst reports. Wells Fargo & Company assumed coverage on shares of Amphastar Pharmaceuticals in a report on Friday, November 22nd. They set an “equal weight” rating and a $55.00 price target for the company. StockNews.com downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $60.33.

Insider Activity at Amphastar Pharmaceuticals

In other news, CFO William J. Peters sold 7,426 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total transaction of $386,523.30. Following the sale, the chief financial officer now directly owns 94,103 shares in the company, valued at approximately $4,898,061.15. The trade was a 7.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Yakob Liawatidewi sold 5,214 shares of the company’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total value of $271,388.70. Following the completion of the transaction, the executive vice president now owns 74,938 shares of the company’s stock, valued at $3,900,522.90. The trade was a 6.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 41,533 shares of company stock worth $1,987,482 over the last three months. Company insiders own 27.10% of the company’s stock.

Amphastar Pharmaceuticals Stock Performance

NASDAQ:AMPH opened at $39.12 on Tuesday. The firm’s 50-day moving average is $46.26 and its 200-day moving average is $44.56. The company has a market cap of $1.88 billion, a price-to-earnings ratio of 13.04, a PEG ratio of 0.87 and a beta of 0.78. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. Amphastar Pharmaceuticals, Inc. has a 52-week low of $36.56 and a 52-week high of $65.92.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.